Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
a study on Uterine Cancer Endometrial Cancer Endometrial Dedifferentiated Carcinoma Endometrial Mixed Cell Adenocarcinoma Endometrial Serous Adenocarcinoma Endometrial Undifferentiated Carcinoma Immunotherapy
Endometrial Clear Cell Adenocarcinoma Endometrial Dedifferentiated Carcinoma Endometrial Endometrioid Adenocarcinoma Endometrial Mixed Cell Adenocarcinoma Endometrial Serous Adenocarcinoma Endometrial Undifferentiated Carcinoma Recurrent Endometrial Adenocarcinoma Recurrent Endometrial Carcinoma Recurrent Endometrial Clear Cell Adenocarcinoma Recurrent Endometrial Dedifferentiated Carcinoma Recurrent Endometrial Endometrioid Adenocarcinoma Recurrent Endometrial Mixed Cell Adenocarcinoma Recurrent Endometrial Serous Adenocarcinoma Recurrent Endometrial Undifferentiated Carcinoma Stage III Uterine Corpus Cancer AJCC v8 Stage IIIA Uterine Corpus Cancer AJCC v8 Stage IIIB Uterine Corpus Cancer AJCC v8 Stage IIIC Uterine Corpus Cancer AJCC v8 Stage IIIC1 Uterine Corpus Cancer AJCC v8 Stage IIIC2 Uterine Corpus Cancer AJCC v8 Stage IV Uterine Corpus Cancer AJCC v8 Stage IVA Uterine Corpus Cancer AJCC v8 Stage IVB Uterine Corpus Cancer AJCC v8 Carcinoma Adenocarcinoma Endometrial Neoplasms Cystadenocarcinoma, Serous Carcinoma, Endometrioid Adenocarcinoma, Clear Cell Paclitaxel Carboplatin Pembrolizumab Albumin-Bound Paclitaxel Quality-of-Life Assessment
Lead Scientists at UC Cancer
- Ramez N. Eskander (ucsd)
Associate Clinical Professor, Ob/Gyn & Reproductive sciences. Authored (or co-authored) 79 research publications.
- Joshua G. Cohen (ucla)
HS Associate Clinical Professor, Obstetrics and Gynecology.
- Krishnansu S. Tewari (uci)
Professor, Obstetrics and Gynecology. Authored (or co-authored) 199 research publications.
- Lee-May Chen (ucsf)
Dr. Lee-may Chen is the Division Director and Program Director for the UCSF/KPSF Gynecologic Oncology Fellowship Program. She is deeply committed to education and improving the outcomes of gynecologic cancer care. Since 2008, I have been the director of the UCSF Gynecologic Cancer Risk Program.
- accepting new patients
- Start Date
- Completion Date
- National Cancer Institute (NCI)
- Phase 3
- Study Type
- Last Updated